Aurinia Pharmaceuticals Inc. (AUPH)
Market Cap | 1.80B |
Revenue (ttm) | 50.12M |
Net Income (ttm) | -102.68M |
Shares Out | 118.47M |
EPS (ttm) | -0.87 |
PE Ratio | n/a |
Forward PE | 1,428.57 |
Dividend | n/a |
Dividend Yield | n/a |
Trading Day | March 1 |
Last Price | $14.00 |
Previous Close | $14.00 |
Change ($) | 0.00 |
Change (%) | 0.00% |
Day's Open | 14.02 |
Day's Range | 13.89 - 14.37 |
Day's Volume | 1,073,095 |
52-Week Range | 9.83 - 20.50 |
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today issued its financial results for the fourth quarter and y...
Aurinia Pharmaceuticals (NASDAQ:AUPH) announces its next round of earnings this Wednesday, February 24. Here is Benzinga's everything-that-matters guide for this Wednesday's Q4 earnings announ...
Aurinia (AUPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participa...
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its fourth quarter and year end 2020 fi...
In the following, I review the recent FDA approval and label for LUPKYNIS and tease out some of the bullish implications. I then consider more factors in the comparison to competitor drug Benl...
Approval of a new lupus treatment has investors buzzing around this biotech stock.
The FDA approved the drugmaker's closely watched lupus nephritis therapy.
AstraZeneca (NASDAQ: AZN) shares are trading higher Monday after the company's CALQUENCE met its primary efficacy endpoint. The German Health Minister also said he expects the EU to approve th...
Aurinia (AUPH) gets approval from the FDA for Lupkynis as a treatment for active lupus nephritis, a disease that causes irreversible kidney damage.
VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today announced that the U.S. Food and Drug Ad...
Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the management team will participate in two ...
Aurinia (AUPH) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
AUPH stock has fallen on two recent developments. I analyze these and argue that the second, a new licensing agreement, is not negative, rather it's a positive for stockholders.
Aurinia Pharmaceuticals has one of the most important milestones in its history in a few weeks. Next January 22, 2021 is the PDUFA where the FDA will decide the approval of the candidate drug ...
Big names like Glaxo, Pfizer and Johnson & Johnson also abandoned promising programs
VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced it has entered into a collabora...
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia”) and Lonza Ltd. (SIX: LONN) ("Lonza") today announced they have expanded their ex...
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced its participation in the Piper Sandler 32nd Annual Virtual H...
In this article we present the list of Top 10 Healthcare Stocks for the Future. Click to skip ahead and see the Top 5 Healthcare Stocks for the Future .
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the senior management team will participate ...
This biotech titan should be a top player on the merger and acquisition scene next year.
Aurinia Pharmaceuticals (AUPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Aurinia (AUPH) delivered earnings and revenue surprises of -27.27% and -50.85%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) fell 0.15% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share decreased 33.33% year over year t...
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Reports Third Quarter 2020 Financial Results and Recent Operational Highlights
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX:AUP) (Aurinia or the Company), a late-stage clinical biopharmaceutical company, today announced da...
Aurinia (AUPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) shares slid on Tuesday after the company reported results from its midstage study for the treatment of dry eye syndrome (DES).
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company, today announce...
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advan...
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advan...
Aurinia's voclosporin demonstrated exceptional Phase 3 trial results to treat Lupus Nephritis “LN”, a significant unmet medical need with blockbuster potential.
Aurinia: Ready For Voclosporin's Positive Jan. 2021 NDA Announcement, 45% Upside
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced Time Is Nephrons, the first-ever lupus nephritis ...
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advan...
Aurinia (AUPH) that it has completed the last patient study visit in the AUDREY study evaluating voclosporin ophthalmic solution for the potential treatment of dry eye syndrome.
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (Aurinia or the Company), a late-stage clinical biopharmaceutical company focused on advancin...
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the senior management team will participate ...
Voclosporin has proven to be a safer and much more effective derivative of cyclosporin, whose emulsion eye drop formulation was approved by FDA in 2003 to treat DES.
Aurinia Pharmaceuticals, Inc.'s (AUPH) CEO Peter Greenleaf on Q2 2020 Results - Earnings Call Transcript
Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) were unchanged after-market trading after the company reported Q2 results.
Aurinia (AUPH) delivered earnings and revenue surprises of -13.04% and -53.23%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
VICTORIA, British Columbia--(BUSINESS WIRE)--AURINIA REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS
Let us take a look at two small biotech companies, VIR and AUPH, which are gearing up for their earnings release.
Aurinia Pharmaceuticals Is A Long-Term Buy With Near-Term Catalysts
Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that Peter Greenleaf, President and Chief Executive Officer ...
About AUPH
Aurinia Pharmaceuticals, a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada.
Industry Biotechnology | IPO Date Jan 26, 1999 |
CEO Peter Greenleaf | |
Stock Exchange NASDAQ | Ticker Symbol AUPH |
Financial Performance
In 2020, AUPH's revenue was $50.12 million, an increase of 15,660.38% compared to the previous year's $318,000. Losses were -$102.68 million, 16.2% more than in 2019.
Analyst Forecasts
According to 9 analysts, the average rating for AUPH stock is "Strong Buy." The 12-month stock price forecast is 11.50, which is a decrease of -17.86% from the latest price.